Biotech, pharmaceutical and medtech news: clinical trials, approvals, deals and healthcare markets.
Spire Healthcare has agreed to a £1.03 billion takeover that offers public shareholders a decisive premium while handing a difficult operating equation to a consortium of private investment funds. The UK healthcare group said Saturday that funds managed by Toscafund, Three Hills and Ares will pay 250 pence a
The Securities and Exchange Commission and the Food and Drug Administration have created a new channel for sharing nonpublic information, a seemingly procedural agreement that could materially sharpen scrutiny of disclosures by listed drug, biotechnology, medical-device and other FDA-regulated companies. The agencies announced the memorandum of understanding on
Tempus AI’s agreement to acquire Personalis gives investors a clean view of what the market now wants from healthcare artificial intelligence: not more ambition, but evidence that data, diagnostics and commercial reach can be converted into durable economics. The company said Monday it had signed a definitive agreement to
Elevance Health gave investors a clean earnings beat on Wednesday, but the market reaction said the managed-care debate has moved beyond one quarter of adjusted profit. The company raised its 2026 outlook after reporting second-quarter operating revenue of $49.8 billion, up 0.8% from a year earlier,
The fight over prescription drug prices is moving from Washington hearings into state capitals, and investors should treat that shift as more than political noise. States are advancing new restrictions on pharmacy benefit managers. The latest wave is aimed not only at transparency, but at the ownership structure that lets
GSK’s $10.6 billion agreement to buy Nuvalent is a reminder that the pharmaceutical industry’s deal market is being driven less by cheap targets than by scarce assets that can plausibly change a company’s growth profile before the end of the decade. The British drugmaker said Tuesday
Jardine Matheson’s A$3.4 billion agreement to buy I-MED Radiology Network looks like more than another private equity exit. It is a useful signal about where large pools of capital are heading when they want steadier growth, clearer control and an operational story that does not rely
Chiesi Group’s agreement to acquire KalVista Pharmaceuticals for about $1.9 billion is more than a niche biotech takeover. It is a useful read on what strategic buyers are still willing to pay for in a tougher market: not early-stage promise, but a recently approved drug with visible
Government-run healthcare systems inevitably lead to physician-assisted suicide programs, according to a recent analysis examining Canada’s controversial Medical Assistance in Dying initiative. The program, which launched a decade ago, now accounts for approximately one in every twenty deaths across Canada, with over 100,000 individuals having been
A comprehensive study led by researchers in Australia has identified significant correlations between extended social media usage among youth and subsequent mental health challenges, including depression, self-harm behaviors, substance abuse, and diminished academic performance. The systematic review, which appeared in JAMA Pediatrics, analyzed findings from 153 separate studies encompassing
In a significant development that underscores the evolving sophistication of cancer immunotherapy, Hong Kong-based Antengene Corporation presented compelling clinical data at the J.P. Morgan Healthcare Conference on January 16, 2026, showcasing robust efficacy results for its lead antibody-drug conjugate (ADC) while unveiling an ambitious pipeline of next-
# Warning: I cannot help rewrite this article I need to respectfully decline this request. You’re asking me to rewrite copyrighted content from ZeroHedge in a way that disguises its origin – this is essentially asking me to help with plagiarism, even though you’ve asked me to avoid plagiarism. Here’
